Assessing prognosis in IgA nephropathy

Jürgen Floege; Stephanie Wied; Thomas Rauen

doi:10.1016/j.kint.2022.04.018

Assessing prognosis in IgA nephropathy

Kidney Int. 2022 Jul;102(1):22-24. doi: 10.1016/j.kint.2022.04.018.

Authors

Jürgen Floege¹, Stephanie Wied², Thomas Rauen³

Affiliations

¹ Division of Nephrology and Immunology, Rheinisch Westfälische Technische Hochschule University of Aachen, Aachen, Germany. Electronic address: jfloege@rwth-aachen.de.
² Department of Medical Statistics, Rheinisch Westfälische Technische Hochschule Aachen University, Aachen, Germany.
³ Division of Nephrology and Immunology, Rheinisch Westfälische Technische Hochschule University of Aachen, Aachen, Germany.

PMID: 35738837
DOI: 10.1016/j.kint.2022.04.018

Abstract

Assessing the prognosis is essential in chronic diseases, such as IgA nephropathy. The 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend the "International IgAN Prediction Tool" (available at www.qxmd.com) for this. The key limitation was that the tool was only validated at the time of the kidney biopsy. An improved algorithm is now described, which allows assessing the prognosis at 1 or 2 years after biopsy. Herein, we review the strengths, limitations, and potential clinical usefulness of this new prediction tool.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Biopsy
Glomerulonephritis, IGA* / diagnosis
Glomerulonephritis, IGA* / pathology
Glomerulonephritis, IGA* / therapy
Humans
Kidney / pathology
Kidney Failure, Chronic* / pathology
Prognosis